1MogenSen CE,Schmitz A,christensen CR.Comparative renal pathophysiology relevant to IDDM and NIDDM Patients[J].Diabetes Metabolism Rev 1998,4:453.
2Brenner BM,Cooper ME,De Zeeuw D,et al.For the RENAAL Study Investigators.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,2001,345:861-869.
3Mudagal M,Patel J,Nagalakshmi N,et al.Renoprotective effects of combining ACE inhibitors and statins in experimental diabetic rats[J].Daru,2011,19(5):322-355.
4Suganami T,Mukoyamma M,Sugawara A,et al.Over-expression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury[J].J Am Soc Nephrol,2001,12(12):2652-2657.
5Chen N,Wang W, Huang Y,et al. Community - based study onCKD subjects and the associated risk factors. Nephrol Dial Trans-plant, 2009,24(7) :2117 -2123.
6Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidneydisease in China: a cross 一 sectional survey. Lancet, 2012, 379(9818) :815 -822.
8De Filippis, Vincenzo, Lancellotti, Stefano, Maser, Fabio et al. Oxidation of Met(1606) in yon Willebrand factor is a risk factor for thrombotic and septic complications in chron- ic renal failure [ J ]. The Biochemical Journal, 2012,442 (2) :423-432.
9Prabhavalkar SM, Mullan RN, Cunningham RG, et al. Asso- ciation between dialysis schedule and mortality in mainte- nance hemodialysis [ J ]. Kidney Int, 2012,82 ( 9 ) : 1034- 1035.
